Last reviewed · How we verify
NCT01896180
A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Latanoprost 0.005%/Dorzolamide 2.0%) to Latanoprost Ophthalmic Solution, 0.005% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension With Intraocular Pressure Inadequately Controlled By Latanoprost
Phase 2 trial testing ALZ-1101 in Primary Open Angle Glaucoma in 63 participants. Completed in 1 January 2014.
1 January 2014
Quick facts
| Lead sponsor | Alleanza Pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 63 |
| Start date | 1 July 2013 |
| Primary completion | 1 January 2014 |
| Estimated completion | 1 January 2014 |
| Sites | 1 location across United States |
Drugs / interventions tested
- ALZ-1101 — full drug profile →
- Latanoprost (LATANOPROST) — full drug profile →
Conditions studied
- Primary Open Angle Glaucoma — all drugs for Primary Open Angle Glaucoma →
- Ocular Hypertension — all drugs for Ocular Hypertension →
- Elevated Intraocular Pressure — all drugs for Elevated Intraocular Pressure →
Sponsor
Alleanza Pharmaceuticals, Inc. — full company profile →
Who can join
18 and older, any sex, with Primary Open Angle Glaucoma or Ocular Hypertension. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Goldmann applanation tonometry
Time frame: 28 days
Between-group comparison of the mean IOP values at the 10 AM time point at Visit 5 (Day 28).
Sponsor's own description
This is a pilot, proof of concept study to evaluate the safety and efficacy of ALZ-1101 dosed once daily for 28 days compared to latanoprost 0.005% ophthalmic solution in patients with elevated intraocular pressure not adequately controlled with latanoprost.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma.
Klimko PG, Sharif NA. · · 2019 · cited 45× · PMID 29665040 · DOI 10.1111/bph.14327
Verify or expand the search:
- PubMed search for NCT01896180
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Open Angle Glaucoma
Currently open trials in the same condition.
- NCT07390890 — DSLT for Reducing Medication in Glaucoma · recruiting
- NCT07447011 — Glaucoma Respsosne to Lifestyle Corrections in Sleep Apnea · NA · recruiting
- NCT07358650 — Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients W · NA · recruiting
- NCT06948773 — A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX) · NA · recruiting
- NCT05439161 — XEN Glaucoma Gel Stent Versus Trabeculectomy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01896180 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alleanza Pharmaceuticals, Inc.
- Last refreshed: 29 September 2014
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01896180.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing